MedTrace Logo

Sildenafil Efficacy Study on Time Walk From Peripheral Arterial Desease Patients (Stade II) With Arterial Claudication

NCT02832570 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2022-07-29

No results posted yet for this study

Summary

Efffect of a single dose oral intake of sildenafil Or placebo on the walking capacity on treadmill of PAD patients with claudication

Conditions

  • Peripheral Arterial Occlusive Disease

Interventions

DRUG

Sildenafil 100mg single oral dose

Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)

DRUG

Placebo, Oral intake single dose

Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)

Sponsors & Collaborators

  • University Hospital, Angers

    lead OTHER_GOV

Principal Investigators

  • Loukman OMARJEE, MD · University Hospital, Angers

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-07
Primary Completion
2017-10-31
Completion
2017-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02832570 on ClinicalTrials.gov